<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833168</url>
  </required_header>
  <id_info>
    <org_study_id>KSN_2016_1_MB</org_study_id>
    <nct_id>NCT02833168</nct_id>
  </id_info>
  <brief_title>Screening Questionnaire for Respiratory Muscle Weakness and Sleep-disordered Breathing in Neuromuscular Disorders</brief_title>
  <official_title>Validation of a German Language Screening Questionnaire for Symptoms of Respiratory Muscle Weakness and Sleep-disordered Breathing in Patients With Neuromuscular Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Westfälische Wilhelms-Universität Münster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Westfälische Wilhelms-Universität Münster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the aim of this project to develop and validate a German language screening&#xD;
      questionnaire for symptoms of respiratory muscle weakness and sleep-disordered breathing&#xD;
      (SDB) in patients with neuromuscular disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SDB is a promiment clinical feature of various neuromuscular disorders including amyotrophic&#xD;
      lateral sclerosis (ALS), spinal muscular atrophy (SMA), and myopathies such as myotonic&#xD;
      dystrophy type 1, Pompe disease, and limb-girdle muscular dystrophies (LGMD). In ALS, SMA,&#xD;
      LGMD and Pompe disease, SDB is usually caused by nocturnal alveolar hypoventilaton due to&#xD;
      diaphragmatic weakness which manifests first during sleep and REM sleep in particular. SDB&#xD;
      usually leads to sleep disruption, non-restorative sleep and daytime symptoms including&#xD;
      morning headache, hypersomnolence, and increased neuromuscular fatigue. In patients with&#xD;
      severe diaphragmatic involvement both symptoms of SDB and potential complications of&#xD;
      respiratory muscle weakness substantially add to overall disease burden of the disease and&#xD;
      decrease life span. Diagnosis of SDB is established by means of sleep studies which should&#xD;
      ideally comprise polysomnography (PSG) and transcutaneous capnography. PSG with capnometry is&#xD;
      time-consuming, expensive and not readily available for patients or referring physicians,&#xD;
      respectively. For this reason it is desirable to thoroughly screen patients with&#xD;
      neuromuscular disease for symptoms of SDB and respiratory muscle weakness. Results from a&#xD;
      validated screening questionnaire could be used as an adjunctive to pulmonary function&#xD;
      testing or spirometry results in order to identify patients in whom sleep studies should be&#xD;
      performed. In addition, a screening questionnaire would facilitate early recognition of&#xD;
      patients with SDB, enabling treating physicians to take appropriate steps to establish the&#xD;
      diagnosis and to initiate non-invasive ventilation as early as possible.&#xD;
&#xD;
      Until now, there is no validated German language screening questionnaire for symptoms of&#xD;
      respiratory muscle weakness and SDB. Steier et al. published an English language&#xD;
      questionnaire which was validated as a screening tool in 33 patients with very different&#xD;
      neuromuscular disorders which were predominantly neurogenic (Steier et al. 2011). In this&#xD;
      study, SDB was defined by an apnea hypopnea index above 5 per hour. Nocturnal oxygen&#xD;
      saturation and CO2 monitoring were not taken into account at all. In addition the&#xD;
      questionnaire does not systematically cover sleep-related symptoms of SDB in detail (such as&#xD;
      sleep disruption and morning headache) which have to be separated from daytime symptoms such&#xD;
      as dyspnea or orthopnea, respectively.&#xD;
&#xD;
      Thus, the current project aims to correlate comprehensively generated items of a screening&#xD;
      questionnaire with sleep study results including capnography alongside with respiratory&#xD;
      muscle testing in patients with neuromuscular disorders. As control subjects, patients with&#xD;
      newly diagnosed obstructive sleep apnea syndrome and sleep disorders other than sleep-related&#xD;
      breathing disorders are enrolled in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nocturnal hypercapnia tcCO2</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Neuromuscular Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with proven neuromuscular disorders known to be potentially associated with significant diaphragmatic weakness, e. g. ALS, myotonic dystrophy type 1, limb-girdle muscular dystrophy, Duchenne and Becker muscular dystrophy. Patients already receiving home ventilatory support will not be included in the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Patient with proven obstructive sleep apnea syndrome prior to CPAP initiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Patients with sleep disorders other than sleep-related breathing disorders, e. g. narcolepsy, hypersomnia, parasomnia or sleep-related movement disorders.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patient-filled questionnaires</intervention_name>
    <description>All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>spiromanometry</intervention_name>
    <description>Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with neuromuscular disorders, newly diagnosed obstructive sleep apnea syndrome or&#xD;
        sleep disorders other than sleep-related breathing disorders (30 patients in each group)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  proven neuromuscular disease known to be potentially associated with diaphragmatic&#xD;
             weakness (group 1)&#xD;
&#xD;
          -  newly diagnosed obstructive sleep apnea with an apnea hypopnea index &gt; 15/h total&#xD;
             sleep time (group 2)&#xD;
&#xD;
          -  newly diagnosed narcolepsy, hypersomnia, insomnia or parasomnia in the absence of any&#xD;
             sleep-related breathing disorder (group 3)&#xD;
&#xD;
          -  availability of recent diagnostic sleep studies including polysomnography and&#xD;
             transcutaneous capnography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ongoing CPAP oder non-invasive ventilation&#xD;
&#xD;
          -  inability to participate in study procedures&#xD;
&#xD;
          -  severe lung disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Boentert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Münster, Department of Sleep Medicine and Neuromuscular Disorders</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Boentert, MD</last_name>
    <phone>+49-251-83</phone>
    <phone_ext>44458</phone_ext>
    <email>matthias.boentert@ukmuenster.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Young, MD</last_name>
    <phone>+49-251-83</phone>
    <phone_ext>48196</phone_ext>
    <email>peter.young@ukmuenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Münster, Department of Sleep Medicine and Neuromuscular Disorders</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Boentert, MD</last_name>
      <phone>+49-251-83</phone>
      <phone_ext>44458</phone_ext>
      <email>matthias.boentert@ukmuenster.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter Young, MD</last_name>
      <phone>+49-251-83</phone>
      <phone_ext>48196</phone_ext>
      <email>peter.young@ukmuenster.de</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias Boentert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Heidbreder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethanien Hospital</name>
      <address>
        <city>Solingen</city>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winfried Randerath, MD</last_name>
      <phone>+49-212 630</phone>
      <phone_ext>0</phone_ext>
      <email>Winfried.Randerath@klinik-bethanien.de</email>
    </contact>
    <contact_backup>
      <last_name>Wiebke Dohrn, MD</last_name>
      <phone>+49-212 630</phone>
      <phone_ext>0</phone_ext>
      <email>Wiebke.Dohrn@klinik-bethanien.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Westfälische Wilhelms-Universität Münster</investigator_affiliation>
    <investigator_full_name>Matthias Boentert</investigator_full_name>
    <investigator_title>MD, Senior Consultant in Neurology and Sleep Medicine</investigator_title>
  </responsible_party>
  <keyword>Neuromuscular disorders</keyword>
  <keyword>Sleep disordered breathing</keyword>
  <keyword>Dyspnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Paresis</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

